Isovitexin Is a Direct Inhibitor of Staphylococcus aureus Coagulase
Author(s) -
Hua Xiang,
Panpan Yang,
Li Wang,
Jiaxin Li,
Tiedong Wang,
Jun-Ze Xue,
Dacheng Wang,
Hongxia Ma
Publication year - 2021
Publication title -
journal of microbiology and biotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 64
eISSN - 1738-8872
pISSN - 1017-7825
DOI - 10.4014/jmb.2105.05013
Subject(s) - staphylococcus aureus , isovitexin , coagulase , microbiology and biotechnology , fibrinogen , fibrin , human pathogen , biology , chemistry , biochemistry , staphylococcus , immunology , bacteria , gene , genetics , flavonoid , vitexin , antioxidant
Staphylococcus aureus ( S. aureus ) is a major pathogen that causes human pneumonia, leading to significant morbidity and mortality. S. aureus coagulase (Coa) triggers the polymerization of fibrin by activating host prothrombin, which then converts fibrinogen to fibrin and contributes to S. aureus pathogenesis and persistent infection. In our research, we demonstrate that isovitexin, an active traditional Chinese medicine component, can inhibit the coagulase activity of Coa but does not interfere with the growth of S. aureus . Furthermore, we show through thermal shift and fluorescence quenching assays that isovitexin directly binds to Coa. Dynamic simulation and structure-activity relationship analyses suggest that V191 and P268 are key amino acid residues responsible for the binding of isovitexin to Coa. Taken together, these data indicate that isovitexin is a direct Coa inhibitor and a promising candidate for drug development against S. aureus infection.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom